PSG sells portion of DoseSpot stake to Bain Capital Tech Opportunities

  • PSG Equity’s DoseSpot investment moved to a partial exit in 2026, with Bain Capital Tech Opportunities buying a portion of PSG’s stake as DoseSpot merged with Arrive Health to form Interra Health.
  • PSG reinvested additional capital in the Interra Health formation, retaining a minority position in the combined platform.
  • DoseSpot expanded beyond ePrescribing via acquisitions of TreatRx, pVerify, and RxLink, adding insurance eligibility verification and medication affordability capabilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PSG Equity LLC published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.